相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anlotinib Induces a T Cell-Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
Yudong Su et al.
CLINICAL CANCER RESEARCH (2022)
Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy
Caicun Zhou et al.
CLINICAL CANCER RESEARCH (2021)
Extranodal NK/T cell lymphoma, nasal type: An updated overview
Celeste Sanchez-Romero et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
Qingli Cui et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
Combination of Immune Checkpoint Inhibitors and Radiotherapy for Advanced Non-Small-Cell Lung Cancer and Prostate Cancer: A Meta-Analysis
Zexi Xu et al.
JOURNAL OF ONCOLOGY (2021)
Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China
Xiangyu Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments
Adrien Procureur et al.
CANCERS (2021)
The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
Chongya Zhai et al.
FRONTIERS IN ONCOLOGY (2021)
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC
Tianqing Chu et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)
Rong Tao et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies
A. Freites-Martinez et al.
ACTAS DERMO-SIFILIOGRAFICAS (2021)
Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance
Hamidah Muhamad et al.
ACTA HAEMATOLOGICA (2020)
Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Changqing Xie et al.
CLINICAL CANCER RESEARCH (2020)
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer
Yinli Yang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population
Paola Ghione et al.
LEUKEMIA & LYMPHOMA (2020)
Combination of anti-PD-1 antibody with P-GEMOX as a potentially effective immunochemotherapy for advanced natural killer/T cell lymphoma
Jun Cai et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Molecular pathogenic pathways in extranodal NK/T cell lymphoma
Sanjay de Mel et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Ming Yi et al.
MOLECULAR CANCER (2019)
Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study
Ewelina Grywalska et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
Yihebali Chi et al.
CLINICAL CANCER RESEARCH (2018)
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Xin Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer The ALTER 0303 Phase 3 Randomized Clinical Trial
Baohui Han et al.
JAMA ONCOLOGY (2018)
PD1 blockade with low-dose nivolumab in NK/T cell lymphoma failing l-asparaginase: efficacy and safety
Thomas S. Y. Chan et al.
ANNALS OF HEMATOLOGY (2018)
Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients
Akihito Kawazoe et al.
GASTRIC CANCER (2017)
Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy
William A. Stokes et al.
JOURNAL OF NEUROIMMUNOLOGY (2017)
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Lin Tian et al.
NATURE (2017)
Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials
Ronald L. Van Heertum et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase
Yok-Lam Kwong et al.
BLOOD (2017)
DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China
Xin Li et al.
CLINICAL CANCER RESEARCH (2016)
Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma
Jing-hua Wang et al.
ONCOTARGET (2016)
First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma
Liang Wang et al.
CANCER (2013)
SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group
Yok-Lam Kwong et al.
BLOOD (2012)
Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study
Arnaud Jaccard et al.
BLOOD (2011)
Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study
Motoko Yamaguchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Radiotherapy as primary treatment for stage IE and IIE nasal natural Killer/T-cell lymphoma
YX Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index
CS Chim et al.
BLOOD (2004)
分享论文
